Videos

Panelists discuss the ongoing challenges and progress in treating non–clear cell renal cell carcinoma (nccRCC), emphasizing the need for subtype-specific trials, mechanistically driven therapy, and international collaboration to move beyond data extrapolation from clear cell RCC (ccRCC) and toward truly evidence-based, personalized care.

Panelists discuss the future of clear cell renal cell carcinoma (ccRCC) treatment, focusing on optimizing sequencing and combinations of existing therapies, integrating novel agents like belzutifan and cellular therapies, and advancing research through clinical trials and investigator-led studies to drive more personalized and effective care.

Panelists discuss how the durability of response data was particularly compelling, with a median duration of response of approximately 2 years and 35% of patients maintaining responses at 3 years, especially noting the surprising 31% response rate in chromophobe renal cell carcinoma (RCC) despite this histology's historically poor responsiveness to immunotherapy due to low tumor mutational burden.

Panelists discuss how the KEYNOTE-B61 study demonstrated remarkable efficacy with a 50.6% objective response rate and 82% disease control rate across all non–clear cell renal cell carcinoma (RCC) histologies, representing a significant improvement over historical tyrosine kinase inhibitor (TKI) data that showed response rates below 30% and setting a new treatment benchmark for this patient population.

A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.

Panelists discuss the ongoing challenge of lacking reliable biomarkers in renal cell carcinoma (RCC), emphasizing promising advances in RNA expression signatures and emerging tools like protein biomarkers and circulating tumor DNA (ctDNA) to personalize treatment and improve real-time therapy decisions despite current limitations.

Although OS data are still immature, they have shown favorable trends for mosunetuzumab and polatuzumab vedotin in transplant-ineligible LBCL.

Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.

Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.

Panelists discuss results from a phase 2 study of nivolumab plus cabozantinib in non–clear cell renal cell carcinoma, highlighting promising efficacy but notable treatment discontinuation rates likely linked to patient complexity, underscoring the need for further research on TKI-IO combinations in this diverse population.

Panelists discuss findings from a landmark European phase 3 trial showing improved overall survival with ipilimumab and nivolumab versus standard therapies in non–clear cell renal cell carcinoma, supporting the role of immune-based combinations across histologic subtypes and reinforcing the need for subtype-specific treatment strategies.

Results from the SUNMO trial may show that M-Pola is a viable treatment option for those with transplant-ineligible relapsed/refractory LBCL.

Experts have a compelling debate on first-line treatment for EGFR-mutated non–small cell lung cancer (NSCLC), weighing the robust survival and central nervous system (CNS) benefits of osimertinib plus chemotherapy against the promise of novel targeted strategies that aim to prevent resistance and push the boundaries of precision oncology.

Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.

Experts partake in a dynamic, debate-style educational event where teams present and challenge current frontline treatment strategies for EGFR-mutant non–small cell lung cancer (NSCLC), focusing on the promise and practical challenges of combination therapy involving a bispecific antibody and third-generation EGFR tyrosine kinase inhibitor (TKI).

CAR T-cell therapies or other agents that affect the immune system in the long term may be important to keep in mind for the management of SCLC.

Experts emphasize that sustained ctDNA negativity beyond 18 to 24 months enables safely extending surveillance intervals, easing patient burden while improving personalized colorectal cancer follow-up despite ongoing challenges with interpretation and insurance coverage.

Panelists discuss how the COCOON trial design represents a straightforward approach using standard practice medications, though implementation challenges include patient compliance with the complex 4-drug regimen requiring significant education and support staff involvement.

Panelists discuss how the COCOON study randomly assigned patients to either standard care or proactive dermatologic management using prophylactic antibiotics, topical treatments, skin moisturization, and anticoagulation to reduce grade 2 or higher dermatologic adverse events.

Experts discuss how integrating ctDNA testing into standard colorectal cancer surveillance enhances early recurrence detection, improves eligibility for curative metastasis-directed therapies, and empowers more personalized, timely treatment decisions, ultimately improving both clinical outcomes and patient confidence.

Marc S. Raab, MD, PhD, details how agents such as carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.

Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.

Patients with mantle cell lymphoma who are older and have less fitness may be eligible for regimens that include bendamustine/rituximab.

Employing patient-reported outcomes may help include those with small cell lung cancer in the shared decision-making process.

Panelists discuss how caregivers can navigate the initial shock of a myeloma diagnosis by seeking reliable information from trusted medical websites, connecting with local support groups, and accessing resources from organizations such as the International Myeloma Foundation (IMF), Multiple Myeloma Research Foundation (MMRF), and patient advocacy groups.

Panelists discuss how Alan Plisskin's multiple myeloma diagnosis began with severe back and hip pain, progressed through life-threatening complications, including seizures and vocal cord paralysis, and revealed extensive lytic lesions throughout his body that required immediate intensive treatment.

Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.

Panelists discuss how the long-term COMMANDS data reveal impressive survival benefits and durable transfusion independence responses, particularly in patients with SF3B1 mutations, while debating whether the observed survival advantage stems from transfusion independence alone or represents true disease modification through broader systemic effects beyond just bone marrow changes.

Panelists discuss how the COMMANDS phase 3 trial data demonstrate long-term efficacy and safety benefits of a newer drug compared with ESA in patients with low-risk myelodysplastic syndromes (MDS), with improved 5-year overall survival rates (54% vs 42%) and sustained transfusion independence lasting over 6 months, while maintaining a well-tolerated safety profile with no new safety signals identified in extended follow-up.

Panelists discuss how toxicity considerations significantly influence treatment selection given multiple effective options, requiring personalized discussions about patient goals, comorbidities, and tolerance for different adverse effect profiles between immune therapy doublets and immunotherapy-tyrosine kinase inhibitor (IO-TKI) combinations.